Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1
Clinical Pharmacokinetics · 2025
DOI: 10.1007/s40262-025-01540-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Steven Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk Inc., 75 Hayden Avenue, Lexington, MA, 02421, USA. xvzn@novonordisk.com. Hauptthemen laut MEDLINE: Hyperoxaluria, Primary, Models, Biological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Nedosiran (Rivfloza®) is an RNA interference (RNAi) therapy approved for individuals aged ≥ 2 years with primary hyperoxaluria type 1 (PH1), a rare autosomal-recessive disorder causing renal failure and systemic oxalosis. Nedosiran silences lactate dehydrogenase (LDH) mRNA in hepatocytes, reducing oxalate levels. This study evaluated the model-informed clinical development of nedosiran to support proposed doses in children aged 2 to < 12 years with PH1. METHODS: A population pharmacokinetic/pharmacodynamic (Pop-PK/PD) model characterizing the plasma concentration-time profile of nedosiran and its effect on the spot urine oxalate-to-creatinine ratio (Uox/Cr) was developed using data from six trials. Simulations assessed spot Uox/Cr reduction in children aged 2 to < 12 years for the proposed dosing regimen versus those aged ≥ 12 years weighing ≥ 50 kg with similar renal function. RESULTS: The datasets included 2087 PK (N = 148) and 668 spot Uox/Cr (N = 41, with PH1) observations. Body weight, estimated glomerular filtration rate (eGFR), and PH type were covariates in the PK model, with body weight in low and high percentiles affecting nedosiran exposures. Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) increased exposure, while only age was significant for baseline Uox/Cr in the PD model. Simulations showed similar Uox/Cr reduction and times to maximum effect in children aged 2 to < 12 years, treated once-monthly (Q1M) with 3.5 mg/kg, compared to those aged ≥ 12 years treated Q1M with 170 mg. CONCLUSIONS: Simulations based on the final Pop-PK/PD model support the 3.5 mg/kg Q1M dosing regimen in children aged 2 to < 12 years with PH1 and relatively intact kidney function (eGFR ≥30 mL/min/1.73 m2). TRIAL REGISTRATION: Trials are registered at ClinicalTrials.gov with study numbers NCT03392896 (PHYOX1), NCT03847909 (PHYOX2), NCT04042402 (PHYOX3), and NCT05001269 (PHYOX8) and at EudraCT with study numbers 2018-003098-91 (PHYOX2) and 2018-003099-10 (PHYOX3).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novo Nordisk Inc., 75 Hayden Avenue, Lexington, MA, 02421, USA. xvzn@novonordisk.com.
- Novo Nordisk Pharma SA, Madrid, Spain.
- Novo Nordisk Inc., 75 Hayden Avenue, Lexington, MA, 02421, USA.
ORCID-Profile: Steven Zhang, Pablo Gamallo
Förderung
- Novo Nordisk
Zitieren
APA
Zhang, S., Gamallo, P., & Rawson, V. (2025). Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01540-1
Vancouver
Zhang S, Gamallo P, Rawson V. Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01540-1
BibTeX
@article{Zhang2025,
author = {Zhang, Steven and Gamallo, Pablo and Rawson, Verity},
title = {Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1},
journal = {Clinical Pharmacokinetics},
year = {2025},
doi = {10.1007/s40262-025-01540-1}
}
EUVIMED